EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Translational Advances in Urothelial Carcinoma: From Bench to Bedside

Tomohiro Iwasawa iD, Takuya Tsujino iD, Shigehiro Tsukahara iD, Hiroshi Fukushima iD, Daisuke Ito iD, Eisuke Tomiyama, Fumihiko Urabe iD, Japanese Young Urologist Basic Research Collaboration

International Journal of Urology · 2026

DOI: 10.1111/iju.70341 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Urology, 2026. Verfasst von Tomohiro Iwasawa und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Keio University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Carcinoma, Transitional Cell, Urinary Bladder Neoplasms. Die Arbeit nennt 99 Literaturangaben. Gefördert von: Nippon Shinyaku.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Urothelial carcinoma (UC), encompassing both bladder cancer and upper tract UC, is a biologically heterogeneous malignancy that has long complicated patient stratification and therapeutic prediction. Recent genomic and transcriptomic analyses, however, have delineated reproducible molecular subtypes across non‐muscle‐invasive and muscle‐invasive disease. These classification frameworks have refined biological understanding and improved both risk stratification and treatment selection. Emerging evidence also indicates that genomic alterations, such as FGFR3 mutations, may confer distinct immunologic phenotypes within specific transcriptomic contexts, thereby challenging prior assumptions. The advent of immune checkpoint inhibitors has transformed UC management, yet variable response rates underscore the complexity of the tumor microenvironment (TME). Single‐cell and spatial analyses have identified immune‐inflamed, ‐desert, and ‐excluded TME subtypes, with cancer‐associated fibroblasts playing a key role in immune exclusion and therapeutic resistance. Liquid biopsy, particularly circulating tumor DNA, has demonstrated utility for real‐time disease monitoring, minimal residual disease detection, and treatment stratification, as highlighted in trials such as IMvigor010 and IMvigor011. Urinary extracellular vesicles also represent promising non‐invasive biomarkers, though further standardization is required. In addition, novel therapeutic strategies—including antibody‐drug conjugates, gene therapies, and sustained‐release delivery systems—are broadening treatment options across disease stages. Collectively, these translational advances mark a paradigm shift toward precision immuno‐oncology in UC. Nonetheless, successful clinical implementation will require prospective validation, optimized analytical platforms, and sustained physician‐scientist engagement to translate these discoveries into improved patient outcomes. This review provides a comprehensive overview of recent progress in UC translational research, with a focus on genomic and transcriptomic insights, the evolving role of immunotherapy, advances in liquid biopsy, and the development of novel therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Transitional CellUrinary Bladder NeoplasmsHumansTumor MicroenvironmentBiomarkers, TumorTranslational Research, BiomedicalImmune Checkpoint InhibitorsLiquid BiopsyExtracellular VesiclesNon-Muscle Invasive Bladder NeoplasmsReceptor, Fibroblast Growth Factor, Type 3

Stichwörter der Autor:innen

BCGcirculating DNAextracellular vesiclesgenomic analysisliquid biopsytranslational researchurothelial carcinoma

Substanzen

Biomarkers, TumorImmune Checkpoint InhibitorsReceptor, Fibroblast Growth Factor, Type 3

Autor:innen und Institutionen

  • Department of Urology, Keio University School of Medicine, Tokyo, Japan.
  • Department of Urology, Osaka Medical and Pharmaceutical University, Osaka, Japan.
  • Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Department of Urology, Institute of Science Tokyo, Tokyo, Japan.
  • Department of Urology, Graduate School of Medicine, The University of Osaka, Osaka, Japan.
  • Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.

ORCID-Profile: Tomohiro Iwasawa, Takuya Tsujino, Shigehiro Tsukahara, Hiroshi Fukushima, Daisuke Ito, Fumihiko Urabe

Förderung

  • Nippon Shinyaku

Zitieren

APA

Iwasawa, T., Tsujino, T., Tsukahara, S., Fukushima, H., Ito, D., Tomiyama, E., Urabe, F., & Japanese Young Urologist Basic Research Collaboration (2026). Translational Advances in Urothelial Carcinoma: From Bench to Bedside. International Journal of Urology. https://doi.org/10.1111/iju.70341

Vancouver

Iwasawa T, Tsujino T, Tsukahara S, Fukushima H, Ito D, Tomiyama E, et al. Translational Advances in Urothelial Carcinoma: From Bench to Bedside. International Journal of Urology. 2026. doi:10.1111/iju.70341

BibTeX
@article{Iwasawa2026,
  author = {Iwasawa, Tomohiro and Tsujino, Takuya and Tsukahara, Shigehiro and Fukushima, Hiroshi and Ito, Daisuke and Tomiyama, Eisuke and Urabe, Fumihiko and Japanese Young Urologist Basic Research Collaboration, Japanese Young Urologist Basic Research Collaboration},
  title = {Translational Advances in Urothelial Carcinoma: From Bench to Bedside},
  journal = {International Journal of Urology},
  year = {2026},
  doi = {10.1111/iju.70341}
}
Kostenlos starten →